Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDALINE: Sonidegib + Docetaxel in TN ABC
NCT02027376Phase 1Completed
- Sponsor
- GEICAM
- Start
- May 2014
- Primary completion
- Apr 2016
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sonidegib in triple-negative breast cancer (TNBC), sponsored by GEICAM. Primary endpoints: Incidence Rate of Dose Limiting Toxicity at Cycle 2, Maximum Tolerated Dose and 1 more. Started May 2014; status: completed.
02
Drugs
sonidegib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02027376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02027376.